June 18, 2020 / 1:13 PM / 20 days ago

BRIEF-Sesen Bio Says FDA Conditionally Accepted Proprietary Brand Name Vicineum For Co's Oportuzumab Monatox

June 18 (Reuters) - Sesen Bio Inc:

* SESEN BIO - ON JUNE 17, U.S. FDA CONDITIONALLY ACCEPTED PROPRIETARY BRAND NAME VICINEUM FOR CO’S PRODUCT CANDIDATE OPORTUZUMAB MONATOX

* SESEN BIO - EXPECTS TO COMPLETE VICINEUM BLA SUBMISSION IN H2 2020, ANTICIPATES POTENTIAL APPROVAL H1 2021

* SESEN BIO - BASED ON FDA FEEDBACK, CO WITHDREW PREVIOUSLY SUBMITTED PROPOSED BRAND NAME, VICINIUM, FROM CONSIDERATION Source text: (bit.ly/2UVJrbE) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below